tomazl Xencor (NASDAQ:XNCR) is an important biotech to keep an eye on, because it has a lot of upcoming catalysts within a 1-year period for investors to look forward to. One of which would be its lead program using vudalimab, which is an anti-PD-1 and anti-CTLA-4 inhibitor in development for the treatment of patients with metastatic castration-resistant prostate cancer in an ongoing phase 2 study. It is expected that monotherapy and combination dose cohorts' data targeting this specific patient population ...